Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $568.11, for a total transaction of $5,397,045.00. Following the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $23,015,840.43. This represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

United Therapeutics Stock Down 0.3%

NASDAQ UTHR traded down $1.59 during trading on Monday, reaching $566.99. 309,647 shares of the stock traded hands, compared to its average volume of 479,020. The firm has a market cap of $24.07 billion, a price-to-earnings ratio of 20.93, a price-to-earnings-growth ratio of 1.84 and a beta of 0.60. The stock’s 50-day moving average price is $558.07 and its 200 day moving average price is $507.69. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.63 EPS. Analysts anticipate that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on UTHR. Bank of America increased their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. UBS Group increased their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Torren Management LLC acquired a new position in United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC boosted its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics during the fourth quarter worth $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.